US20040052807A1 - Synthetic vaccine for tick control - Google Patents
Synthetic vaccine for tick control Download PDFInfo
- Publication number
- US20040052807A1 US20040052807A1 US10/275,304 US27530403A US2004052807A1 US 20040052807 A1 US20040052807 A1 US 20040052807A1 US 27530403 A US27530403 A US 27530403A US 2004052807 A1 US2004052807 A1 US 2004052807A1
- Authority
- US
- United States
- Prior art keywords
- synthetic
- inoculated
- terminal
- protein
- bovines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940126577 synthetic vaccine Drugs 0.000 title claims abstract 5
- 241000283690 Bos taurus Species 0.000 claims abstract description 25
- 241000238876 Acari Species 0.000 claims abstract description 18
- 235000018102 proteins Nutrition 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 235000001014 amino acid Nutrition 0.000 claims abstract description 11
- 230000002163 immunogen Effects 0.000 claims abstract description 10
- 108010008038 Synthetic Vaccines Proteins 0.000 claims abstract description 9
- 238000010276 construction Methods 0.000 claims abstract description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000018417 cysteine Nutrition 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 5
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 4
- 230000001850 reproductive effect Effects 0.000 claims abstract 4
- 241000238680 Rhipicephalus microplus Species 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 21
- 229960005486 vaccine Drugs 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 230000028993 immune response Effects 0.000 abstract description 5
- 238000013461 design Methods 0.000 abstract description 2
- 230000003902 lesion Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 19
- 235000013601 eggs Nutrition 0.000 description 17
- 230000009467 reduction Effects 0.000 description 15
- 238000011081 inoculation Methods 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 244000045947 parasite Species 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- 206010061217 Infestation Diseases 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 239000008223 sterile water Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 230000000895 acaricidal effect Effects 0.000 description 3
- 239000000642 acaricide Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 244000078703 ectoparasite Species 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000606665 Anaplasma marginale Species 0.000 description 2
- 241000223838 Babesia bovis Species 0.000 description 2
- UUOYKFNULIOCGJ-GUBZILKMSA-N Cys-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CS)N UUOYKFNULIOCGJ-GUBZILKMSA-N 0.000 description 2
- SRIRHERUAMYIOQ-CIUDSAMLSA-N Cys-Leu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O SRIRHERUAMYIOQ-CIUDSAMLSA-N 0.000 description 2
- 108010090461 DFG peptide Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YOZCKMXHBYKOMQ-IHRRRGAJSA-N Leu-Arg-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N YOZCKMXHBYKOMQ-IHRRRGAJSA-N 0.000 description 2
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 2
- SPCHLZUWJTYZFC-IHRRRGAJSA-N Lys-His-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(O)=O SPCHLZUWJTYZFC-IHRRRGAJSA-N 0.000 description 2
- 241001502576 Potato mop-top virus Species 0.000 description 2
- QYDKSNXSBXZPFK-ZJDVBMNYSA-N Thr-Thr-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYDKSNXSBXZPFK-ZJDVBMNYSA-N 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000017448 oviposition Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- RAAWHFXHAACDFT-FXQIFTODSA-N Ala-Met-Asn Chemical compound CSCC[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](CC(N)=O)C(O)=O RAAWHFXHAACDFT-FXQIFTODSA-N 0.000 description 1
- DCGLNNVKIZXQOJ-FXQIFTODSA-N Arg-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N DCGLNNVKIZXQOJ-FXQIFTODSA-N 0.000 description 1
- 206010003399 Arthropod bite Diseases 0.000 description 1
- BRCVLJZIIFBSPF-ZLUOBGJFSA-N Asn-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N BRCVLJZIIFBSPF-ZLUOBGJFSA-N 0.000 description 1
- QQXOYLWJQUPXJU-WHFBIAKZSA-N Asp-Cys-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O QQXOYLWJQUPXJU-WHFBIAKZSA-N 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000223840 Babesia bigemina Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001302652 Bassiana Species 0.000 description 1
- 241000283699 Bos indicus Species 0.000 description 1
- GCDLPNRHPWBKJJ-WDSKDSINSA-N Cys-Gly-Glu Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O GCDLPNRHPWBKJJ-WDSKDSINSA-N 0.000 description 1
- RJPKQCFHEPPTGL-ZLUOBGJFSA-N Cys-Ser-Asp Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O RJPKQCFHEPPTGL-ZLUOBGJFSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WVWZIPOJECFDAG-AVGNSLFASA-N Glu-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N WVWZIPOJECFDAG-AVGNSLFASA-N 0.000 description 1
- ZTNHPMZHAILHRB-JSGCOSHPSA-N Glu-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)NCC(O)=O)=CNC2=C1 ZTNHPMZHAILHRB-JSGCOSHPSA-N 0.000 description 1
- NZAFOTBEULLEQB-WDSKDSINSA-N Gly-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN NZAFOTBEULLEQB-WDSKDSINSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 229910003019 MBH4 Inorganic materials 0.000 description 1
- DBOMZJOESVYERT-GUBZILKMSA-N Met-Asn-Met Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCSC)C(=O)O)N DBOMZJOESVYERT-GUBZILKMSA-N 0.000 description 1
- 241000223250 Metarhizium anisopliae Species 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 1
- PDUVELWDJZOUEI-IHRRRGAJSA-N Phe-Cys-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PDUVELWDJZOUEI-IHRRRGAJSA-N 0.000 description 1
- WPTYDQPGBMDUBI-QWRGUYRKSA-N Phe-Gly-Asn Chemical compound N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O WPTYDQPGBMDUBI-QWRGUYRKSA-N 0.000 description 1
- 241000868180 Pheidole megacephala Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- OLIJLNWFEQEFDM-SRVKXCTJSA-N Ser-Asp-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLIJLNWFEQEFDM-SRVKXCTJSA-N 0.000 description 1
- DLPXTCTVNDTYGJ-JBDRJPRFSA-N Ser-Ile-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(O)=O DLPXTCTVNDTYGJ-JBDRJPRFSA-N 0.000 description 1
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 1
- 208000004374 Tick Bites Diseases 0.000 description 1
- FEZASNVQLJQBHW-CABZTGNLSA-N Trp-Gly-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O)=CNC2=C1 FEZASNVQLJQBHW-CABZTGNLSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 244000000054 animal parasite Species 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000032669 eclosion Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 210000000087 hemolymph Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 108010018006 histidylserine Proteins 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention is closely related to the fields of protein biotechnology, immunology and particularly with the construction of synthetic immunogens which result, when inoculated in cattle, in the production by cattle of an immune response capable of lesion to the ticks feeding on the inoculated bovines, reducing the number of bovines, their weight and capacity of reproduction to such an extent that the constructed immunogen can be used as an effective vaccine for tick control in bovines.
- tick Boophilus microplus (Canestrini, 1887), belonging to the Ixodoidae family, is the main bovine ectoparasite in Brazil and in all tropical and subtropical countries. This parasite is extremely well adapted to the climate of a large part of the country and, coupled with the presence of its hosts distributed over more than 80% of the nation's territory, constitutes a major problem to cattle raising in Brazil.
- the associated losses are not limited to the drop in production resulting from the intense hemophagia, but can also be related to other damages such as the inoculation of toxins from the salivary glands, depreciation of the hides, influencing the productive capacity of the animals and, chiefly, the transmission of various microorganisms that cause diseases which seriously affect cattle raising in the nation, such as Babesia bovis and Babesa bigemina , with participation also in the epidemiology of Anaplasma marginale.
- a number of approaches are used at present for tick control and the treatment of bovines with acaricides, which are chemical substances that kill the ticks.
- This methodology of control is disadvantageous in that a resistance is built against the chemicals in various tick populations, which necessarily leads to the introduction of new chemical substances for the control; the frequency of chemical treatments in an attempt at effective control of ticks in cattle herds; the harm that such chemical substances can cause to animals, the human health and the environment.
- Another alternative are the crosses of Bos taurus taurus and Bos taurus indicus, but these hybrids have a lower productive capacity than pure breeds, specifically in the case of dairy cattle, the use of chemical substances being necessary for the control stopping short of building tick resistance in such crossings.
- Still another proposed alternative for control is the use of pastures which would function in the non-parasitic phase of the parasite. Pasture rotation is also seen as an option since, depending on the resting time of each portion of the pasture, the born larvae would consume their food reserves and die before installing themselves in a host.
- the use of natural tick predators such as long-legged birds and birds of prey has also been researched, but the biologic and food chain risks of introducing such animals are not yet known.
- the ant Pheidole megacephala has been the subject of research as an alternative of less ecological impact. Natural parasites such as some bacteries and fungi of the species Beauvenia bassiana and Metarhizium anisopliae have also been analyzed.
- the third vaccine would come in 1996, the TickGard Plus®, which has been successfully tested in various bovine breeds (WILLADSEN et al, Veterinary Parasitology 71: 209-222. 1997).
- tick control vaccine based on the chemical synthesis of an immunogen would be more advantageous than a recombinant vaccine, such as high purity, because it does not require costly and complex purification techniques, its complete chemical characterization, it is safe because of the absence of contaminants, complete large-scale reproducibility, high stability, since it does not contain enzymes and other proteinaceous materials derived from other biologic materials, making its storage easier, and lower cost of production on an industrial scale.
- the novelty of the present invention consists of the design and construction of two synthetic immunogens constituted of a continuous and defined sequence of forty-three (43) amino acids found in different positions in the protein Bm86 sequence, their polymerization with cysteines in the N-terminal and the C-terminal, the medicamentous composition based on said synthetic polypeptide(s) and the vaccine obtained thereby.
- the object of the present invention is constituted of the continuous and definitive of the forty-three amino acids, the manner of their polymerization using cysteine in their terminals, their medicamentous composition, thereby constituting the synthetic immunogen which can be advantageously used in the control by immunoprophylaxis of the bovine Boophilus microplus tick.
- FIG. 1 shows the kinetics of antibodies in animals made immune by peptide SBm4912.
- FIG. 2 shows kinetics of antibodies in animals made immune by SBm7462 peptide.
- the peptides were formed having in view the structure of the Bm86 protein.
- the choice of these peptides within the structure of the integrate protein has been based on studies of computer prediction of immunogenic sites based on the protein properties, such as being antigenetic (HOOP and WOODS, 1981, Proceedings of the National Academy of Science , U.S.A. 78:3824-3828), potential of alpha and beta helixes and Beta Sheet (CHOU and FASMAN, 1978 , Advances of Enzymology of Relative Areas in Molecular Biology 47:45-148), hydrophobicity and hydrophilic properties (KYTE and DOOLITTLE, 1982 , Journal of Molecular Biology 157:105-132).
- DIEA diisopropylethylamine
- DCC dicyclohexylcarbodiimide
- Bos taurus taurus calves 8 to 10 months old were inoculated. These animals were kept in isolation, free from the infestation of ticks, flies and other ectoparasites. These animals were separated into four groups, with four animals in each group.
- Group 1 Control, which was inoculated with 4 ml of sterile water milliQ, via subcutaneous, in three (3) doses, the first one on day zero (0), the second one on day 30 and the third one on day 60.
- Group 2 Seponin, inoculated with 1.5 mg of saponin adjuvant diluted in 4 ml of sterile water milliQ, administered via subcutaneous on the same dates of inoculation of the Control group.
- Group 3 Inoculated with the synthetic peptide named SBm4912 (Synthetic Boophilus microplus 4912), in a solution of 2.0 mg of synthetic peptide and 1.5 mg of saponin adjuvant, diluted in 4 ml of sterile water milliQ, administered via subcutaneous, following the same time schedule established for the other groups.
- SBm4912 Synthetic Boophilus microplus 4912
- Group 4 Inoculated with the synthetic peptide named SBm7462 (Synthetic Boophilus microplus 7462), inoculated with 4 ml of a solution containing 1.5 mg of saponin adjuvant and 2.0 mg of synthetic peptide diluted in sterile water milliQ, administered via subcutaneous on the same dates as the preceding groups.
- SBm7462 Synthetic Boophilus microplus 7462
- Peptides SBm4912 and SBm7462 did not cause when inoculated adverse reactions or discomfort to the inoculated animals.
- a vaccine for tick control based on the chemical synthesis of an immunogen offers advantages such as:
- Table 1 shows the Biological parameters of Boophilus microplus from animals inoculated with the synthetic peptides and from the control group and the adjuvant control group.
- the letters (a, b, c) indicate significant statistical differences at the significance level of 0.01% in the Tukey Test.
Abstract
This invention is related to the field of immunology of protein biotechnology and particularly to the construction of synthetic immunogens which result, where inoculated, in the production by cattle of an immune response capable of lesion to the ticks feeding on the inoculated bovines, reducing their number, their weight and their reproductive capacity to such an extent that the constructed immunogen can be used as an effective vaccine for tick control on bovines. The technical object of the invention consists of the design and construction of two synthetic immunogens constituted of a continuous and defined sequence with forty-three (43) amino acids, found in different positions in the sequence of protein Bm86, their polymerization with cysteine in the N-terminal and in the C-terminal, the medicamentous composition based on said peptide(s) and the synthetic vaccine obtained thereby.
Description
- This invention is closely related to the fields of protein biotechnology, immunology and particularly with the construction of synthetic immunogens which result, when inoculated in cattle, in the production by cattle of an immune response capable of lesion to the ticks feeding on the inoculated bovines, reducing the number of bovines, their weight and capacity of reproduction to such an extent that the constructed immunogen can be used as an effective vaccine for tick control in bovines.
- The tickBoophilus microplus (Canestrini, 1887), belonging to the Ixodoidae family, is the main bovine ectoparasite in Brazil and in all tropical and subtropical countries. This parasite is extremely well adapted to the climate of a large part of the country and, coupled with the presence of its hosts distributed over more than 80% of the nation's territory, constitutes a major problem to cattle raising in Brazil. The associated losses are not limited to the drop in production resulting from the intense hemophagia, but can also be related to other damages such as the inoculation of toxins from the salivary glands, depreciation of the hides, influencing the productive capacity of the animals and, chiefly, the transmission of various microorganisms that cause diseases which seriously affect cattle raising in the nation, such as Babesia bovis and Babesa bigemina, with participation also in the epidemiology of Anaplasma marginale.
- The damage to livestock caused by ticks manifests itself by various typical actions, such as direct damage by the intense hematophagia originating mainly from the female ticks, and which can be as much as 0.6 to 3 ml per adult female. This results basically in loss of production, and various trials have been conducted to assess this situation. In 1987 (HOLROYD et al.,Australian Journal of Experimental Agriculture 28: 1:10) observed that animals which had not been touched by ticks had gained on average 17 kg over a period of three years, as compared to those animals exposed to the parasite. In Brazil, (BRANCO et al 1987, Coletânea de Pesquisas EMBPAPA/CNPO, p. 229-234), found an average weight gain of 34.5 kg in Hereford cattle. In the country, FURLONG 1996 observed a reduced milk production in successive increasing infestations. JONSSON et al (Veterinary Parasitology 78: 66-77, 1998) have estimated that each adult female would be responsible for a drop of 8.9 ml in daily milk production and 1.0 g in loss of weight.
- The loss caused by the tick bite and the consequent local inflammation adversely affect the value of the hide, which is of great concern in traditional areas of leather production.
- The inoculation of toxins when sucking the blood, natural components of the tick saliva such as prostaglandin inhibitors and other modulators of the inflammatory response, which can lead to a hypersensibility reaction, paralysis of the members and even to testicular hypotrophy.
- As to the transmission of pathogenic agents, the important ones in Brazil are the protozoaBabesia bovis and Babesia bigemina, with participation also in the epidemiology of Anaplasma marginale (PATARROYO, 1994, Revista de Patologia Tropical 23:145-146).
- One must also include as losses to Brazilian livestock industry the costs of direct control of ticks and of the diseases for which they are carriers. HORN and ATECHE 1985 (A Hora Veterinária 4:12-32) have estimated the direct and indirect losses at 800 million dollars. The Ministry of Agriculture, in a paper covering the two years 1983/1984, raises that amount to one billion dollars per year, of which 40% represent losses in milk production. A paper by HORN in 1988 (Programa nacional de controle de parasitoses, in Curso de Parasitologia Animal 2:21-42) mentions expenditures of US$ 13,800,000.00 with acaricides, which would represent 15% of the nation's total cost of protection.
- A number of approaches are used at present for tick control and the treatment of bovines with acaricides, which are chemical substances that kill the ticks. This methodology of control is disadvantageous in that a resistance is built against the chemicals in various tick populations, which necessarily leads to the introduction of new chemical substances for the control; the frequency of chemical treatments in an attempt at effective control of ticks in cattle herds; the harm that such chemical substances can cause to animals, the human health and the environment. Another alternative are the crosses of Bos taurus taurus and Bos taurus indicus, but these hybrids have a lower productive capacity than pure breeds, specifically in the case of dairy cattle, the use of chemical substances being necessary for the control stopping short of building tick resistance in such crossings. Still another proposed alternative for control is the use of pastures which would function in the non-parasitic phase of the parasite. Pasture rotation is also seen as an option since, depending on the resting time of each portion of the pasture, the born larvae would consume their food reserves and die before installing themselves in a host. The use of natural tick predators such as long-legged birds and birds of prey has also been researched, but the biologic and food chain risks of introducing such animals are not yet known. The antPheidole megacephala has been the subject of research as an alternative of less ecological impact. Natural parasites such as some bacteries and fungi of the species Beauvenia bassiana and Metarhizium anisopliae have also been analyzed. Another attempt at control has been the use of interspecific crossings of tick species to generate infertile males, but the frequency of intraspecific crossings exceeded that of interspecific crossings. All of the systems mentioned have problems of a practical nature, from the economic and/or ecological standpoints, which prevents their use in most of the geographical cattle raising areas.
- In contrast to the foregoing description, the possibility of use of an effective vaccine for tick control constitutes an attractive alternative as compared to the methods available and in use at present.
- Various attempts have been made to obtain immunization against the infestation of ticks in bovines. For the purpose of identifying the proteinaceous component and the organ in which the protective immunogenic factor would be found, larvae extracts, nervous tissue, hemocytes, hemolymph, genital tract, and eggs ofBoophilus microplus were used, but these attempts were unsuccessful (DAVIDSON, S. 1985, Rural Research 128: 4-8; OPDEBEECK et al., 1988, Immunology 63: 363-367).
- In 1989, (WILLADSEN et al., Journal of Immunology 143: 1346-1351) finally isolated and purified a protein which mimicked the alterations found with the gross tick extracts. That glycoprotein was designated Bm86, with an estimated weight of 89 kDa and a pl of 5.5. Subsequently, the amino acid sequence of this protein was determined, and it was found that the sequence was composed of 650 amino acids, of which 10% were cystein, showing a great analogy with the growth factor of the human epidermis (RAND et al, 1989, Proceedings of the National Academic Sciences USA 86:9657-9661).
- By means of immunohistochemical techniques and monoclonal panels, the location and distribution of Bm86 in the tick's intestine were determined, and were found in the microvillosities of the membrane of the intestine epithelial cells and highly concentrated near the basal membrane (GOUGH and KEMP, 1933, Journal of Parasitology 79:900-907; LEE and OPDEBEECK, 1994, International Journal of Parasitology 25: 241-248).
- Trials of vaccination with this protein reportedly show that the antibodies produced in bovines against the protein, as well as those generated by the inoculation of tick intestine extracts, are aggressive to the intestinal epithelium of the parasite, causing irreparable damage which will later affect the biological cycle of this ectoparasite.
- Genetic studies which propitiated large-scale production of the protein through DNA cloning which encodes the Bm86 asEscherichia coli (TELLAM et al, 1992, Animal Parasite Control Using Biotechnology: 303-331), as Aspergilus nidulans and as Baculovirus (TURNBULL et al, 1990, Applied Environmental Microbiology 56: 2847-2852; TELAMM et al. 1992), have been performed, as well as vaccination trials, with up to 70% protection in some cases, resulting in a decrease of tick growth and affecting its biological cycle. Then, in 1994 the first vaccine against tick, named TickGard® was commercially launched, through genetic engineering techniques in E. coli (SMITH et al, 1995).
- In 1994 the second commercial vaccine againstBoophilus microplus was launched under the trade name Gavac®, it was developed by Cuban research groups who expressed Bm86 in the yeast Pichia pastoris (RODRIGUEZ et al, Journal of Biotechnology 33: 135-146, 1994).
- The third vaccine would come in 1996, the TickGard Plus®, which has been successfully tested in various bovine breeds (WILLADSEN et al,Veterinary Parasitology 71: 209-222. 1997).
- Notwithstanding the foregoing description, where it is shown that the use of commercial immunogens can result in significant reduction of infestation, they do not yet offer levels of protection which would make the use of conventional acaricides.
- The purification procedures and obtention of immunogens for ticks in natura require an extremely ample and complex procedure. On the other hand, obtaining recombinant proteins requires the inconvenient preparation and handling of extensive cell cultures, either the fermentation or others intended for getting the proteinaceous material necessary for mass immunization, which is costly and may involve highly complex technical problems.
- Obtaining new immunogens which can function as alternatives and/or complements to those already described represents a considerable advance in the development of effective vaccines.
- In this context, we can note the propensity for new research, prompted by the recent progress of the knowledge in the areas of immunology, biochemistry, cell biology and biotechnology, for control of these parasites by vaccination.
- Taking into account the fact that a protein can have several epitopes in its structure, which can act as protecting factors or not, and which can even be a mechanism of parasite mimicking to evade the immune response, it would be greatly advantageous to utilize vaccines having determinate and characterized epitopes, since this would avoid some problems brought about by the epitopes which are not necessary for developing protection and immunity against the parasite, such as suppressing, allergic and/or self-immune mechanisms, and typical evasion mechanisms of microorganisms.
- Thus, a tick control vaccine based on the chemical synthesis of an immunogen would be more advantageous than a recombinant vaccine, such as high purity, because it does not require costly and complex purification techniques, its complete chemical characterization, it is safe because of the absence of contaminants, complete large-scale reproducibility, high stability, since it does not contain enzymes and other proteinaceous materials derived from other biologic materials, making its storage easier, and lower cost of production on an industrial scale.
- The novelty of the present invention consists of the design and construction of two synthetic immunogens constituted of a continuous and defined sequence of forty-three (43) amino acids found in different positions in the protein Bm86 sequence, their polymerization with cysteines in the N-terminal and the C-terminal, the medicamentous composition based on said synthetic polypeptide(s) and the vaccine obtained thereby.
- Therefore, the object of the present invention is constituted of the continuous and definitive of the forty-three amino acids, the manner of their polymerization using cysteine in their terminals, their medicamentous composition, thereby constituting the synthetic immunogen which can be advantageously used in the control by immunoprophylaxis of the bovineBoophilus microplus tick.
- FIG. 1 shows the kinetics of antibodies in animals made immune by peptide SBm4912.
- FIG. 2 shows kinetics of antibodies in animals made immune by SBm7462 peptide.
- The peptides were formed having in view the structure of the Bm86 protein. The choice of these peptides within the structure of the integrate protein has been based on studies of computer prediction of immunogenic sites based on the protein properties, such as being antigenetic (HOOP and WOODS, 1981, Proceedings of theNational Academy of Science, U.S.A. 78:3824-3828), potential of alpha and beta helixes and Beta Sheet (CHOU and FASMAN, 1978, Advances of Enzymology of Relative Areas in Molecular Biology 47:45-148), hydrophobicity and hydrophilic properties (KYTE and DOOLITTLE, 1982, Journal of Molecular Biology 157:105-132).
- The synthesis was made in accordance with a known technique as described in (MERRIFIELD 1963, Journal of the American Chemistry Society 85: 2149). The methodology employed was the Good Manufacture Procedure (GMP), where a solid support is employed, in our case resin MBH4 (4-methylbenzidrilamine) with a substitution coefficient of 0.49 meq/g, weighed in accordance with the amount of peptides to be synthesized and amino acids protected in their side chains by the t-boc group (terbutylcarbonyl). The resin was placed in a polyethylene bag which was heat-sealed. A solution of 100 ml of diisopropylethylamine (DIEA) 5% in dicyclohexylcarbodiimide (DCC) was added to activate the resin. The bag was dried and a solution of the first amino acid dissolved in dichloromethane (DCM) solvent or a solution of dimethylformamide (DMF) plus the DCC activator were added, with the amount of amino acid depending on its molecular weight and on the amount and type of the resin employed. These were incubated and stirred for one hour at room temperature. After this incubation, the bag of synthetic material was taken out, one of its ends was cut and a small portion of the resin was removed to check the full coupling of the amino acid to the resin, by the ninhydrin test. With the positive test, the coupling was repeated using 1-hydroxybenzotriazole (HOBT) hydrate. With the negative test, the synthesis continued, by the addition of 100 ml of trifluoroacetic acid (TFA) in DCM to withdraw the protection of amino groups, washing with DCM and isopropanol and incubation with the next amino acid of the peptide sequence. At the end of the synthesis, the material was subjected to cleavages for removal of the t-boc groups and the resin, and to HPLC chromatography to determine the level of efficiency and purity of the synthesis, subsequently lyophilized and then stored in eppendorf tubes containing 40 mg at the temperature of −20° C.
- In order to test the capacity of the peptides in inducing a protective immune response, Bos taurus taurus calves 8 to 10 months old were inoculated. These animals were kept in isolation, free from the infestation of ticks, flies and other ectoparasites. These animals were separated into four groups, with four animals in each group.
- Group 1—Control, which was inoculated with 4 ml of sterile water milliQ, via subcutaneous, in three (3) doses, the first one on day zero (0), the second one on day 30 and the third one on day 60.
-
Group 2—Saponin, inoculated with 1.5 mg of saponin adjuvant diluted in 4 ml of sterile water milliQ, administered via subcutaneous on the same dates of inoculation of the Control group. - Group 3—Inoculated with the synthetic peptide named SBm4912 (SyntheticBoophilus microplus 4912), in a solution of 2.0 mg of synthetic peptide and 1.5 mg of saponin adjuvant, diluted in 4 ml of sterile water milliQ, administered via subcutaneous, following the same time schedule established for the other groups.
- Group 4—Inoculated with the synthetic peptide named SBm7462 (SyntheticBoophilus microplus 7462), inoculated with 4 ml of a solution containing 1.5 mg of saponin adjuvant and 2.0 mg of synthetic peptide diluted in sterile water milliQ, administered via subcutaneous on the same dates as the preceding groups.
- The animals were constantly monitored twice a day during five days following inoculation to check for possible reactions of cutaneous hypersensibility to peptides and the adjuvant. To identify possible hemolytic effects of the peptides (CALVO et al, 1991, Peptides Research 4:324-333) in addition to daily visual inspection of the inoculation point, hematocrit tests were made in all the animals within five days following inoculation.
- After 21 days from the last inoculation, the animals were challenged with larvae ofBoophilus microplus amounting to 1500 larvae per day during three successive days, for a total of 4500 larvae per animal.
- Clinical observations were made weekly until the eighteenth day and daily thereafter, to check the development and predict the probable day when shedding the adult females would start.
- On the twenty-first day, when the females began to fall, a procedure was initiated to collect all adult females found on the floor of the bays, in the feeding trough and on the sewage disposal grate. For a more careful collection, the bay was washed twice a day and all of the material resulting from the washing was sifted and the adult females were removed and identified according to the bay from which they came and the inoculation group. The females were then individually packed and identified. Each female was weighed on a precision scale and left for egg laying during 15 days in a B.O.D. stove at 27° C. and 80% humidity (OBA, 1976, Revista da Faculdade de Veterinária e Zootecnia da Universidade de São Paulo, 13:409-420), at which time the eggs of each tick were weighed. These eggs were cut into 20 portions of 75 mg each (1500 eggs) per group and incubated for 30 days in a B.O.D. stove, with daily observation of the eclosion process. The larvae were then weighed on a precision scale (MASSARD et al, 1995, Revista Brasileira de Medicina Veterinária 17:167-173). To assess the effect of the synthetic immunogens on the biological parameters of the ticks, the formulae recommended by DE LA FUENTE for the rBM86 (Recombinant vaccines for the control of cattle tick, Habana: Elpos Scientiae, 280 p., 1995) were used for each vaccine group and for the control group and the control of the adjuvant, as shown below:
DT(%) = 100[1-(NTV/NTC)] where: DT(%) Percent reduction of number of adult females NTV Number of adult females per each vaccine group NTC Number of adult females in Control group DR(%) = 100[1-(PMTV/PMTC)] where: DR(%) Percent reduction of average adult females weight PMTV Average weight of adult females for each vaccine group PMTC Average weight of adult females in Control group DO(%) = 100 [1-(PMOV/PMOC)] where: DO(%) Percent reduction of average egg weight PMOV Average egg weight for each vaccine group PMOC Average egg weight in Control group DF(%) = 100[1-PPLOV/PPLOC] where: DF(%) Reduction in the fertility of the eggs PPLOV Average weight of larvae per gram of eggs in each vaccine group PPLOC Average weight of larvae per gram of eggs in Control group EF(%) = 100[1-(CRT × CRO × CRF)] where: EF(%) Effectiveness of peptide used as a vaccine CRT Reduction in the number of adult females CRO Reduction in egg laying capacity CRF Reduction in fertility - In order to assess the kinetics of synthetic anti-peptide antibodies produced in the inoculated bovines, blood samples were taken. The collection of blood of the animals in this experiment observed the following schedule: two weekly collections before the first inoculation, four weekly collections after the first inoculation, four weekly collections after the second inoculation, and six weekly collections after the third inoculation. The serum obtained from each sample was aliquoted into eppendorf tubes at −20° C. The kinetics was measured using the ELISA immunoenzymatic test.
- The data on the biological parameters analyzed after counting and weighting the adult females, weighting eggs and larvae, are shown in Table 1, as well as the parameters of the reduction in number and weight of the adult females, the weight of the eggs, the fertility and the effectiveness.
- It could be observed that the adult females loosened from the animals vaccinated with the synthetic peptides SBm4912 and SBn7462 had a lower weight and statistically different from the control and saporin groups, not significantly different among themselves. In the analysis of the average weight of the eggs, it was found that the results from groups 3 and 4 were significantly lower than those of the Control group, and statistically equal among themselves. In weighing the ratio larvae/gram of eggs, the picture obtained was similar to the preceding one.
- In comparing the percentage factors of reduction in weight and number of adult females, of the weights of eggs and larvae, the conclusion is that the SBm4912 and SB7462 peptides obtained a significant level of reduction and effectiveness. The kinetics of anti-peptide antibodies (IgG) appears to be a typical IgG immune response produced by a non-synthetic antigen, these results are shown in FIGS. 1 and 2.
- Peptides SBm4912 and SBm7462 did not cause when inoculated adverse reactions or discomfort to the inoculated animals.
- Advantages of the Proposed Solution:
- A vaccine for tick control based on the chemical synthesis of an immunogen offers advantages such as:
- its high level of purity because it does not require expensive and complex purification techniques;
- its full chemical characterization;
- safety as to the absence of contaminants;
- full reproducibility on a large scale;
- high stability as it does contain enzymes and other proteinaceous materials from other biological materials, which makes its storage easier;
- low cost of production on an industrial scale.
- The following Table 1 shows the Biological parameters ofBoophilus microplus from animals inoculated with the synthetic peptides and from the control group and the adjuvant control group. The letters (a, b, c) indicate significant statistical differences at the significance level of 0.01% in the Tukey Test.
TABLE 1 Biological Groups parameters Control Saponin 4912 7462 Average adult 0.31586a 0.314124a 0.280386b 0.289074b Females weight Average egg- 0.159087a 0.16805a 0.111706b 0.115292b laying weight Weight of 0.857a 0.828a 0.617b 0.573b larvae/gram of eggs Weight 8.328%a 5.448%b reduction adult females (DR) Weight 29.78%a 27.53%b reduction of eggs (DO) Reduction of 45.39%a 60.92%b adult females (DT) Reduction of 28.04%a 33.12%a fertility (DF) Effectiveness 72.4%a 81.05%b (EF) - The object of this invention is likely to be improved and modified, without disrupting the essence of the concept and scope of the invention, which is limited only by the scope of attached claims.
-
1 2 1 45 PRT Artificial Sequence Description of Artificial Sequence synthetic Boophilus microplus 4912 1 Cys Leu Ser Lys His Val Leu Arg Lys Leu Gln Ala Cys Glu His Ser 1 5 10 15 Ser Ile Cys Ser Asp Phe Gly Asn Glu Phe Cys Arg Asn Ala Cys Asp 20 25 30 Cys Gly Glu Trp Gly Ala Met Asn Met Thr Thr Arg Cys 35 40 45 2 45 PRT Artificial Sequence Description of Artificial Sequence synthetic Boophilus microplus 7462 2 Cys Leu Ser Lys His Val Leu Arg Lys Leu Gln Ala Cys Glu His Cys 1 5 10 15 Asp Cys Gly Glu Trp Gly Ala Met Asn Met Thr Thr Arg Ser Ser Ile 20 25 30 Cys Ser Asp Phe Gly Asn Glu Phe Cys Arg Asn Ala Cys 35 40 45
Claims (3)
1. A synthetic vaccine against ticks characterized by the construction of the synthetic immunogen SBm4912 (Synthetic Boophilus microplus 4912), constituted of a continuous and defined sequence with forty-three (43) amino acids found in different positions in the sequence of protein Bm86, its polymerization with cysteine in the N-terminal and in the C-terminal, CLSKHVLRKLQACEHSSICSDFGNEFCRNACDCGEWGAMNMTTRC, which, when inoculated on bovines is characterized by producing immunity against ticks, reducing their number and their reproductive capacity.
2. A synthetic vaccine against ticks characterized by the construction of the synthetic immunogen SBm7462 (Synthetic Boophilus microplus 7462), constituted of a continuous and defined sequence with forty-three (43) amino acids found in different positions in the sequence of protein Bm86, its polymerization with cysteine in the N-terminal and in the C-terminal, CLSKHVLRKLQACEHCDCGEWGAMNMTTRSSICSDFGNEFCRNAC, which, when inoculated on bovines is characterized by producing immunity against ticks, reducing their number and their reproductive capacity.
3. The medicamentous composition of the synthetic vaccine against ticks, formed by the synthetic immunogen SBm4912 or SBm7462 plus an adequate adjuvant, in any dosage of the mixture characterized by the use of these synthetic immunogens which are thus characterized by producing immunity against ticks, reducing their numbers and their reproductive capacity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/190,816 US8110202B2 (en) | 2000-05-04 | 2005-07-28 | Synthetic vaccine for tick control |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0001717-5B1A BR0001717B1 (en) | 2000-05-04 | 2000-05-04 | SYNTHETIC VACCINE FOR TICK CONTROL |
BRPI0001717-5 | 2000-05-04 | ||
PCT/BR2001/000057 WO2001082957A1 (en) | 2000-05-04 | 2001-05-04 | Snthetic vaccine for tick control |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/190,816 Continuation US8110202B2 (en) | 2000-05-04 | 2005-07-28 | Synthetic vaccine for tick control |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040052807A1 true US20040052807A1 (en) | 2004-03-18 |
Family
ID=3944119
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/275,304 Abandoned US20040052807A1 (en) | 2000-05-04 | 2001-05-04 | Synthetic vaccine for tick control |
US11/190,816 Expired - Fee Related US8110202B2 (en) | 2000-05-04 | 2005-07-28 | Synthetic vaccine for tick control |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/190,816 Expired - Fee Related US8110202B2 (en) | 2000-05-04 | 2005-07-28 | Synthetic vaccine for tick control |
Country Status (10)
Country | Link |
---|---|
US (2) | US20040052807A1 (en) |
EP (1) | EP1289545B1 (en) |
AT (1) | ATE496632T1 (en) |
AU (1) | AU779537B2 (en) |
BR (1) | BR0001717B1 (en) |
DE (1) | DE60143940D1 (en) |
ES (1) | ES2360430T3 (en) |
MX (1) | MXPA02010851A (en) |
PT (1) | PT1289545E (en) |
WO (1) | WO2001082957A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060168573A1 (en) * | 2005-01-14 | 2006-07-27 | Clark William A | Method and apparatus for building an electronic product |
WO2014159052A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Vaccination of companion animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission |
US9556244B2 (en) | 2012-05-24 | 2017-01-31 | The United States Of America, As Represented By The Secretary Of Agriculture | Vaccination of animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2352946B1 (en) * | 2008-04-16 | 2012-01-23 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) | SYSTEM FOR THE EXPRESSION OF PEPTIDES ON THE BACTERIAL SURFACE. |
BR102013026625B1 (en) | 2013-10-16 | 2022-04-26 | Universidade Federal de Viçosa | Recombinant peptide vaccine for tick control and nucleotide sequences encoding recombinant peptides |
CN104007215B (en) * | 2014-05-07 | 2015-08-26 | 广东药学院 | The construction method of fairy maiden Chinese medicine sieve finger-print |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235283B1 (en) * | 1986-11-27 | 2001-05-22 | Biotechnology Australia Pty. Ltd. | DNA encoding a cell membrane glycoprotein of a tick gut |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US869657A (en) | 1907-05-21 | 1907-10-29 | J W Flanagan | Clam-shell bucket. |
ZA932352B (en) | 1993-04-01 | 1994-06-10 | Centro De Ingeneria Genetica Y | Procedure for the production of a tick particulated antigen in pichia pastoris yeast and the vaccinepreparation obtained |
EP0725838A4 (en) * | 1993-10-26 | 1997-02-26 | United Biomedical Inc | Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics |
-
2000
- 2000-05-04 BR BRPI0001717-5B1A patent/BR0001717B1/en active IP Right Grant
-
2001
- 2001-05-04 AU AU54538/01A patent/AU779537B2/en not_active Ceased
- 2001-05-04 WO PCT/BR2001/000057 patent/WO2001082957A1/en active IP Right Grant
- 2001-05-04 AT AT01927509T patent/ATE496632T1/en not_active IP Right Cessation
- 2001-05-04 EP EP01927509A patent/EP1289545B1/en not_active Expired - Lifetime
- 2001-05-04 ES ES01927509T patent/ES2360430T3/en not_active Expired - Lifetime
- 2001-05-04 DE DE60143940T patent/DE60143940D1/en not_active Expired - Lifetime
- 2001-05-04 PT PT01927509T patent/PT1289545E/en unknown
- 2001-05-04 US US10/275,304 patent/US20040052807A1/en not_active Abandoned
- 2001-05-04 MX MXPA02010851A patent/MXPA02010851A/en active IP Right Grant
-
2005
- 2005-07-28 US US11/190,816 patent/US8110202B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235283B1 (en) * | 1986-11-27 | 2001-05-22 | Biotechnology Australia Pty. Ltd. | DNA encoding a cell membrane glycoprotein of a tick gut |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060168573A1 (en) * | 2005-01-14 | 2006-07-27 | Clark William A | Method and apparatus for building an electronic product |
US20060167577A1 (en) * | 2005-01-14 | 2006-07-27 | Clark William A | System and method of manufacturing a customized product |
US9556244B2 (en) | 2012-05-24 | 2017-01-31 | The United States Of America, As Represented By The Secretary Of Agriculture | Vaccination of animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission |
WO2014159052A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Vaccination of companion animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission |
US9408896B2 (en) | 2013-03-13 | 2016-08-09 | The United States Of America, As Represented By The Secretary Of Agriculture | Vaccination of companion animals to elicit a protective immune response against tick infestations and tick-borne pathogen transmission |
Also Published As
Publication number | Publication date |
---|---|
PT1289545E (en) | 2011-05-03 |
EP1289545B1 (en) | 2011-01-26 |
ES2360430T3 (en) | 2011-06-03 |
BR0001717A (en) | 2002-03-19 |
US8110202B2 (en) | 2012-02-07 |
AU5453801A (en) | 2001-11-12 |
WO2001082957A1 (en) | 2001-11-08 |
US20050281836A1 (en) | 2005-12-22 |
BR0001717B1 (en) | 2013-10-08 |
DE60143940D1 (en) | 2011-03-10 |
AU779537B2 (en) | 2005-01-27 |
ATE496632T1 (en) | 2011-02-15 |
EP1289545A1 (en) | 2003-03-12 |
MXPA02010851A (en) | 2004-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Patarroyo et al. | Immunization of cattle with synthetic peptides derived from the Boophilus microplus gut protein (Bm86) | |
KNOX | Development of vaccines against gastrointestinal nematodes | |
US8110202B2 (en) | Synthetic vaccine for tick control | |
US8629260B2 (en) | Anti-arthropod vector vaccines, methods of selecting and uses thereof | |
US9085634B2 (en) | Vaccine composition for controlling ectoparasite infestations | |
Tsuda et al. | cDNA cloning, characterization and vaccine effect analysis of Haemaphysalis longicornis tick saliva proteins | |
Mukherjee et al. | Orally active acaricidal peptide toxins from spider venom | |
Boulanger et al. | Vaccination of goats against the trematode Schistosoma bovis with a recombinant homologous schistosome‐derived glutathione S‐transferase | |
Cupp et al. | Evaluation of a recombinant salivary gland protein (thrombostasin) as a vaccine candidate to disrupt blood-feeding by horn flies | |
Das et al. | Assessment of protective response induced by whole antigens of fish ectoparasite, Argulus siamensis in rohu, Labeo rohita | |
Ghosh et al. | Progress in development of vaccine against Hyalomma anatolicum anatolicum—Indian scenario | |
NO342822B1 (en) | Vaccine inducing an immune response to copepods and / or a mucus shield in fish comprising peptide combinations, and the use of the peptides to produce a vaccine. | |
EP1399549B1 (en) | Anticomplement polypeptide from salivary glands of the tick ixodes ricinus | |
US5861160A (en) | Isospora suis sporozoite antigen | |
US10052369B2 (en) | Aquaporin 2 protects cattle from ticks and tick-borne parasites | |
Mumcuoglu et al. | Immunization of rabbits with faecal extract of Pediculus humanus, the human body louse: effects on louse development and reproduction | |
AU664054B2 (en) | Flystrike antigen and vaccine and method for preparation | |
JP4925236B2 (en) | Vaccine containing tick cement protein | |
Kamau | Isolation, Recombinant Expression and Characterization of Polymorphism of BM86 Vaccine Antigen Homologues from rhipicephalus appendiculatus | |
AU2013200258A1 (en) | Peptide sequences and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |